inositol has been researched along with Mental Disorders in 13 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clinical trials indicate that inositol may be effective in the treatment of patients with depression, panic disorder and obsessive compulsive disorder (OCD), but not in the treatment of patients with schizophrenia, Alzheimer's disease, ADHD or autism." | 4.81 | The effects of inositol treatment in animal models of psychiatric disorders. ( Belmaker, RH; Einat, H, 2001) |
| "Inositol is a simple polyol precursor in a second messenger system important in the brain." | 2.68 | Controlled trials of inositol in psychiatry. ( Levine, J, 1997) |
| "Myo-inositol is an important part of the phosphatidylinositol second messenger system (PI-cycle)." | 2.43 | A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies. ( Kim, H; McGrath, BM; Silverstone, PH, 2005) |
| "The cognitive decline in Alzheimer's disease (AD) patients has been reported to involve alterations in the medial temporal lobe and the posterior cingulate gyrus." | 1.34 | A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. ( Horiguchi, J; Inagaki, T; Inami, Y; Kawamukai, T; Miyaoka, T; Okazaki, S; Shinno, H; Utani, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rafii, MS | 1 |
| Skotko, BG | 1 |
| McDonough, ME | 1 |
| Pulsifer, M | 1 |
| Evans, C | 1 |
| Doran, E | 1 |
| Muranevici, G | 1 |
| Kesslak, P | 1 |
| Abushakra, S | 1 |
| Lott, IT | 1 |
| Cho, YU | 1 |
| Lee, D | 1 |
| Lee, JE | 1 |
| Kim, KH | 1 |
| Lee, DY | 1 |
| Jung, YC | 1 |
| Toker, L | 1 |
| Agam, G | 2 |
| GARCIA-BUNUEL, L | 1 |
| GARCIA-BUNUEL, M | 1 |
| Kim, H | 1 |
| McGrath, BM | 1 |
| Silverstone, PH | 1 |
| Mason, GF | 1 |
| Krystal, JH | 1 |
| Shinno, H | 1 |
| Inagaki, T | 1 |
| Miyaoka, T | 1 |
| Okazaki, S | 1 |
| Kawamukai, T | 1 |
| Utani, E | 1 |
| Inami, Y | 1 |
| Horiguchi, J | 1 |
| Kaplan, BJ | 1 |
| Shannon, S | 1 |
| Belmaker, RH | 2 |
| Bersudsky, Y | 1 |
| Benjamin, J | 1 |
| Levine, J | 3 |
| Kofman, O | 1 |
| Grisaru, N | 1 |
| Pies, R | 1 |
| Einat, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia[NCT01791725] | Phase 2 | 23 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder[NCT02811133] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2023-08-31 | Withdrawn (stopped due to Funding terminated) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Neuropsychiatric Inventory(NPI) (Cummings et al 1994) is a behavioral measure that assesses psychopathology in dementia patients. The NPI was administered at the Baseline Visit (Day 1) and at Day 28 (EOS) or ET. A decrease in score shows an improvement in symptoms. (NCT01791725)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) |
|---|---|
| ELND005 BID | 7 |
| ELND005 QD | 0 |
| Placebo | 1 |
For all AE summaries, if a patient had more than one AE within a preferred term, the patient was counted only once, at the maximum severity and with the closest relationship to study drug. If a patient had more than one AE within a SOC, the subject was similarly counted only once when reporting results for that SOC. (NCT01791725)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| ELND005 BID | 5 |
| ELND005 QD | 2 |
| Placebo | 0 |
Subjects with Abnormal Neurological Examination Results (NCT01791725)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Baseline | Week 4 | |
| ELND005 BID | 4 | 4 |
| ELND005 QD | 1 | 1 |
| Placebo | 3 | 3 |
Rapid Assessment for Development Disabilities (RADD) The RADD test was developed from the low-difficulty items from published intelligence tests (Walsh et al 2007). It was specifically developed for evaluation of individuals with intellectual disabilities and developmental disabilities. It is a validated and reliable cognitive screening instrument that can be rapidly administered. The RADD is composed of 76 items. Each item is scored as 0 (incorrect) or 1 (correct).The test assesses a wide range of functional abilities including receptive and expressive language, orientation, registration, recall, attention, self identification, motor skills, imitation, abstract reasoning, number skills, comprehension and short-term memory to give a total score. Scores are from 0 to 76. A higher total score is correlated with a higher Cognitive Impairment level. (NCT01791725)
Timeframe: Baseline and 4 Weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Day 0 | Week 4 | |
| ELND005 BID | 58.7 | 59.1 |
| ELND005 QD | 58.0 | 64.3 |
| Placebo | 62.2 | 62.8 |
Mean Plasma ELND005 Concentrations- Cmax (NCT01791725)
Timeframe: Baseline and 4 Weeks
| Intervention | μg/mL (Mean) | |
|---|---|---|
| Mean Cmax, First Dose, Day 0 | Mean Cmax, Last Dose, Day 28 | |
| ELND005 BID | 1.68 | 6.33 |
| ELND005 QD | 2.61 | 4.48 |
| Placebo | 0 | 0 |
6 reviews available for inositol and Mental Disorders
| Article | Year |
|---|---|
A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies.
Topics: Bipolar Disorder; Feeding and Eating Disorders; Humans; Inositol; Magnetic Resonance Spectroscopy; M | 2005 |
MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases.
Topics: Aspartic Acid; Biomarkers; Choline; Drug Evaluation; Humans; Inositol; Magnetic Resonance Spectrosco | 2006 |
Manipulation of inositol-linked second messenger systems as a therapeutic strategy in psychiatry.
Topics: Animals; Humans; Inositol; Lithium; Mental Disorders; Second Messenger Systems | 1995 |
[Inositol treatment in medicine].
Topics: Animals; Humans; Inositol; Inositol Phosphates; Mental Disorders; Metabolic Diseases; Models, Biolog | 1996 |
Adverse neuropsychiatric reactions to herbal and over-the-counter "antidepressants".
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Dehydroepiandrosterone; Depressive D | 2000 |
The effects of inositol treatment in animal models of psychiatric disorders.
Topics: Affect; Animals; Arousal; Depressive Disorder; Disease Models, Animal; Humans; Inositol; Mental Diso | 2001 |
2 trials available for inositol and Mental Disorders
| Article | Year |
|---|---|
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia.
Topics: Administration, Oral; Adolescent; Adult; Cognition Disorders; Double-Blind Method; Down Syndrome; El | 2017 |
Controlled trials of inositol in psychiatry.
Topics: Adult; Alzheimer Disease; Depressive Disorder; Double-Blind Method; Female; Humans; Inositol; Male; | 1997 |
5 other studies available for inositol and Mental Disorders
| Article | Year |
|---|---|
Exploratory metabolomics of biomarker identification for the internet gaming disorder in young Korean males.
Topics: Aspartic Acid; Behavior, Addictive; Biomarkers; Blood Chemical Analysis; Gas Chromatography-Mass Spe | 2017 |
Lithium, inositol and mitochondria.
Topics: Animals; Antimanic Agents; Autophagy; Humans; Inositol; Lithium Compounds; Mental Disorders; Mitocho | 2014 |
CEREBROSPINAL FLUID LEVELS OF FREE MYOINOSITOL IN SOME NEUROLOGICAL DISORDERS.
Topics: Biochemical Phenomena; Biochemistry; Cerebrospinal Fluid; Child; Dementia; Diabetic Neuropathies; Ge | 1965 |
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Cognition Disorders; Cre | 2007 |
Nutritional aspects of child and adolescent psychopharmacology.
Topics: Adolescent; Child; Dietary Supplements; Drug Interactions; Food; Food-Drug Interactions; Humans; Ino | 2007 |